This section
of the Web site describes the clinical trials currently open to enrollment
at the Beth Israel AIDS Clinical Trials Unit (ACTU) in New York. New
clinical trials are added frequently, so please check this listing
often or call the Aids Clinical Trials Unit now at: 212.420.4519 or toll free 800.483.7339 to get the most up-to-date trial information.
ID Code |
Description |
Eligibility |
No Prior Treatment
|
Pfizer A4001078 |
NO LONGER RECRUITING. No Prior Treatment. Pilot study of Maraviroc + ATV/R vs. ATV/r + Truvada in HIV ARV Naïve, R5 Positive Patients |
Inclusion Criteria
- HIV RNA > 1,000 copies/ml
- CD4 > 100
- Trofile R5 Positive
Exclusion Criteria
- Prior treatment with any other HIV antiretroviral therapy for more than 14 days at any time.
- Acute illness or Acute HIV-related OI
- Renal Insuffiency
|
Tibotec TMC278-TIDP6-C209 |
NO LONGER RECRUITING.Phase 3 Double blind trial of TMC278 vs EFV in combination with a fixed background regimen in Naïve subjects
Study Arms
Blinded TMC-278 vs Efavirenz with background Truvada (FTC + TDF) |
- HIV positive
- HIV-1 RNA >5,000 copies/ML
- Antiretroviral naïve
- Must Not Have Documented resistance to NNRTI’s
|
Prior HIV Treatment/ Undetectable
Viral Load
|
|
No available trials at this time. Please check back periodically. |
|
Prior HIV Treatment/Detectable
Viral Load
|
Gilead GS-0144
|
OPEN TO ENROLLMENT. Phase 3 Double-blind Study of the Safety and Efficacy of Ritonavir-boosted Elvitegravir vs. Raltegravir in Antiretroviral-Experienced Adults
Study Arms
Ritonavir-boosted PI + Elvitegravir + Background regimen vs. Ritonavir-boosted PI + Raltegravir + Background regimen |
- HIV Plasma RNA >1000
- Stable antiretroviral regimen for at least 30 days prior to screening
- No prior treatment with any integrase inhibitor
- Fully active boosted PI regimen on genotype
|
Pfizer A4001067 |
OPEN TO ENROLLMENT.An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients (POEM)
|
- Ages Eligible for Study: 18 Years and older
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers: No
- Sampling Method: Non-Probability
- Sample
Study Population
Treatment experienced, HIV-1 infected patients in routine clinical practice.
-
Inclusion Criteria
- Treatment experienced,
- HIV-1 infected patients
- 18 years or older
- Receive an approved assay for determination of HIV-1 tropism
- Exclusion Criteria:
- Pregnant or lactating
- Using CCR5 inhibitor other than maraviroc
|
ANTIBIOTIC STUDIES |
|
No available trials at this time. Please check back periodically. |
|
OTHER STUDIES
|
PHS 398/2590 |
OPEN TO ENROLLMENT. Serum Antibodies to Recombinant Pneumocystis Antigen
Study Arms
- HIV positive with history of PCP
- HIV negative controls
|
|
MV21542 (PROPHESYS 3) |
OPEN TO ENROLLMENT. A Prospective Observational Study On Predictors of Early on-treatment Response and Sustained Virological Response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons |
Inclusion/Exclusion criteria:
- HIV and HCV co-infection only
- No history of prior treatment with pegylated interferon and/or ribavirin
- No Co-infection with Hepatitis B
|
Join a Clinical Trial Today |
